Skip to main content
HCPCS Q2056 · Level II · Part B drug

HCPCS Q2056: Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation

Reviewed by QuickIntell RCM Editorial Team · Last reviewed

Data effective
Data currency: ASP payment limits October 2026 (effective October 1, 2026); MUE and NCCI edits 2026 Q4 (effective October 1, 2026); OPPS Addendum B July 2026 (effective July 1, 2026). Next CMS release: January 1, 2027 (ASP, MUE, NCCI and OPPS quarterly updates).

Key facts for Q2056

Billing unit
up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells
Ciltacabtagene car-pos t
ASP payment limit
$594,112.255
October 2026; +1.0% vs July 2026
Practitioner MUE
none published
CMS publishes no MUE for this code
OPPS status
SI K
APC 9498
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS Q2056 is the Level II code for Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation, billed per up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells. The Medicare Part B ASP payment limit for October 2026 is $594,112.255 per billing unit, up 1.0% from July 2026. Under OPPS it carries status indicator K in APC 9498. Q2056 is billed in units of up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells; the quantity administered, the NDC package and the units on the claim must reconcile, which is the check that prevents CARC 16 and 151 returns on this line. The ASP crosswalk maps 2 NDCs to it, sold as Carvykti by Janssen Biotech, Inc.. No current Billing and Coding Article lists Q2056, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for Q2056 at $594,112.255 per up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells for October 2026, derived from manufacturer average sales price plus 6%, compared with $587,977.755 in July 2026. Beneficiary coinsurance is 19%.

ASP payment limits for Q2056
QuarterPayment limitPerCoinsurance
October 2026$594,112.255up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells19%
July 2026$587,977.755up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells—
CMS note: Inflation-adjusted coinsurance

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 2 NDCs from 1 labeler to Q2056. Report the NDC in the claim's drug segment and bill the number of Q2056 units that equals the quantity administered divided by up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells; the last column gives units per full package.

NDCs that crosswalk to Q2056
NDCDrug nameLabelerPackage sizeBilling units / package
57894-0111-01CarvyktiJanssen Biotech, Inc.1 × 11
57894-0111-02CarvyktiJanssen Biotech, Inc.1 × 11

Medically Unlikely Edits (MUE)

CMS does not publish an MUE for Q2056 in the 2026 Q4 tables. Some MUE values are confidential and applied without publication, so unit limits can still deny; document the dose and the units calculation on every claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists Q2056 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

Q2056 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists Q2056 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the July 2026 OPPS Addendum B, Q2056 carries status indicator K and is assigned to APC 9498, with a published national unadjusted payment of $587,977.76. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Common denials for Q2056 and how to prevent them

CARC 16 · M119

NDC missing, invalid or not matched to the HCPCS code

CARC 151 · N362

units billed exceed the MUE for the date of service

CARC 50 · N115

diagnosis not covered by the applicable coverage article or LCD

How QuickIntell checks Q2056 before the claim leaves

QuickCode validates the NDC-to-unit conversion against the current ASP crosswalk, checks units against every published MUE setting and flags PTP and add-on conflicts on the same claim. QuickRCM routes CARC 16, 151 and 50 denials on drug lines with the matching coverage article attached so the appeal starts with evidence.

Explore QuickCodeExplore QuickRCMBook a meeting

Frequently asked questions — HCPCS Q2056

What does HCPCS code Q2056 describe?

Q2056 is defined by CMS as "Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation". Each billing unit represents up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, so the units reported on the claim must equal the dose administered divided by that unit.

What is the Medicare reimbursement for Q2056 in October 2026?

The ASP-based payment limit is $594,112.255 per up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, with 19% beneficiary coinsurance. Medicare Administrative Contractors apply this limit; commercial payers use their own fee schedules. The July 2026 limit was $587,977.755.

Which NDCs map to Q2056?

The October 2026 ASP crosswalk lists 2 NDCs from 1 labeler: Carvykti (Janssen Biotech, Inc.). For example NDC 57894-0111-01 is a 1 package equal to 1 billing unit. The crosswalk's billing-units-per-package figure converts each package into Q2056 units.

Does Q2056 have NCCI bundling edits?

No active practitioner PTP pairs list Q2056 as a column-1 or column-2 code in the v323r0 release. Unit limits (MUE) and medical-necessity coverage rules still apply.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-10-02. Verify against the primary file before billing or contracting decisions.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B and the Medicare Coverage Database. Payment limits are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.